UK – Merck’s Keytruda recommended by NICE to reduce risk of lung cancer recurrence

Merck & Co’s – known as MSD outside the US and Canada – Keytruda (pembrolizumab) has been recommended by the National Institute of Health and Care Excellence (NICE) to treat resectable non-small cell lung cancer (NSCLC) in adults at a high risk of disease recurrence.

Par
RIS.WORLD
-

The anti-PD-1 therapy has been specifically recommended for use in combination with platinum-based chemotherapy as a neoadjuvant treatment before surgery and then as a monotherapy in the adjuvant setting after surgery.

Lung cancer is the third most common cancer in the UK and NSCLC accounts for approximately 90% of all cases…

ARTICLES CONNEXESPLUS DE L'AUTEUR